MARKET

CYCCP

CYCCP

Cyclacel Phar Pr
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.10
+0.62
+9.57%
Closed 16:00 05/25 EDT
OPEN
7.00
PREV CLOSE
7.10
HIGH
7.10
LOW
7.00
VOLUME
10
TURNOVER
2.94K
52 WEEK HIGH
11.17
52 WEEK LOW
5.17
MARKET CAP
2.38M
P/E (TTM)
-3.4634
1D
5D
1M
3M
1Y
5Y
Cyclacel Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
- Oral Fadraciclib Demonstrating Strong Safety Profile with Continuous Dosing; anticipate entering Phase 2 POC in 2H 2022 - - First Patients Dosed in Phase 1/2 Study of Oral PLK1 Inhibitor CYC140 for Treatment of Advanced Solid Tumors and Lymphomas - - Pub...
GlobeNewswire · 05/11 20:05
Cyclacel Pharmaceuticals to Release First Quarter 2022 Financial Results
BERKELEY HEIGHTS, N.J., May 04, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce firs...
GlobeNewswire · 05/04 13:15
BRIEF-Cyclacel Doses First Patient In Phase 1/2 Study Of Oral CYC140
reuters.com · 04/19 13:19
Cyclacel Announces Dosing Of First Patient In Phase 1/2 Study Of Oral Cyc140 In Patients With Advanced Solid Tumors And Lymphomas
- CYC140, a Potent and Selective PLK1 Inhibitor to Be Evaluated as a Single Agent Across Multiple Solid Tumor and Lymphoma Types in Streamlined, Registration-Directed Study - BERKELEY HEIGHTS, N.J., April 19, 2022
Benzinga · 04/19 13:17
Cyclacel Pharmaceuticals Doses First Patient in Phase 1/2 Trial of Potential Treatment for Advanced Solid Tumors
MT Newswires · 04/19 11:56
We're Keeping An Eye On Cyclacel Pharmaceuticals' (NASDAQ:CYCC) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Simply Wall St. · 04/15 12:33
Cyclacel Pharmaceuticals Announces Publication Confirming Fadraciclib Suppresses MCL1 And Synergizes With Venetoclax In Chronic Lymphocytic Leukemia
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", , Cyclacel", , or the ", , Company", , )))), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today
Benzinga · 04/12 11:06
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2021 Financial Results
BERKELEY HEIGHTS, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fo...
GlobeNewswire · 03/22 11:00
More
No Data
Learn about the latest financial forecast of CYCCP. Analyze the recent business situations of Cyclacel Phar Pr through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.55%
Pharmaceuticals & Medical Research
+0.01%
Key Executives
Non-Executive Chairman/Independent Director
Christopher Henney
President/Chief Executive Officer/Director
Spiro Rombotis
Chief Financial Officer/Chief Operating Officer/Executive Vice President - Finance/Secretary/Director
Paul Mcbarron
Senior Vice President
Mark Kirschbaum
Independent Director
Samuel Barker
Independent Director
Gregory Hradsky
Independent Director
Brian Schwartz
Independent Director
Lloyd Sems
Independent Director
Robert Spiegel
Independent Director
Karin Walker
No Data
No Data
About CYCCP
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The Company is focused on the field of cancer cell cycle biology with a vision to improve patient healthcare by translating insights in cancer biology into medicines that can overcome resistance and ultimately increase a patient’s overall survival. The Company's pipeline includes Fadraciclib, CYC140 and Sapacitabine. The Fadraciclib is a cyclin dependent kinase (CDK) inhibitor selectively targeting Cyclin Dependent Kinase 2 (CDK2) and Cyclin-dependent kinase 9 (CDK9). The CYC140 is a novel, small molecule, selective and potent PLK-centric inhibitor. The Company's Sapacitabine (CYC682) is an orally available nucleoside analogue with a DNA damage response (DDR) mechanism.

Webull offers kinds of Cyclacel Pharmaceuticals Inc stock information, including NASDAQ:CYCCP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYCCP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CYCCP stock methods without spending real money on the virtual paper trading platform.